Why the study?
Does transcatheter arterial embolization reduce serum angiotensin-converting enzyme levels in patients with liver cirrhosis and hepatocellular carcinoma?
Does transcatheter arterial embolization reduce serum angiotensin-converting enzyme levels in patients with liver cirrhosis and hepatocellular carcinoma?
Elevated serum ACE in liver cirrhosis is likely due to reduced hepatic clearance, which can be partially reversed by improving hepatic blood flow via transcatheter arterial embolization.
Embolization may lower ACE via improved hepatic clearance in cirrhosis with HCC; leaves open effects on clinical outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ohno et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: